Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Faruqi & Faruqi LLPFSLR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds First Solar (FSLR) Investors of Securities Class Action Lawsuit Deadline on August 24, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In First Solar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in First Solar between February 26, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile...
- Faruqi & Faruqi LLPBTU UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Peabody Energy Investors of Securities Class Action Lawsuit Deadline on August 24, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Peabody Energy To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Peabody Energy between October 14, 2024 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]New York, New York--(Newsfile...
- Galvanize Therapeutics, Inc.Galvanize Therapeutics® Announces the Latest Exploratory Evidence Suggesting Immune-Activating Potential of Aliya® PEF EnergyNew clinical data published in Clinical Cancer Research , together with independent recognition in Nature Cancer , suggest Aliya PEF may help create an organized immune response within tumors, adding to growing body of evidence that its effects may extend beyond local ablation. REDWOOD...
- Richardson Electronics, Ltd.Richardson Electronics, Ltd. to Deliver Energy Storage Solutions to Remote Alaska CommunitiesMulti-million-dollar program includes an 18-system, 7 MWh deployment, demonstrating growing energy storage capabilities
- Kaplan Fox & Kilsheimer LLPKaplan Fox Encourages Investors of Bloom Energy Corporation (BE) to Act Ahead of the Lead Plaintiff Deadline on September 28, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Bloom Energy Corporation ("Bloom Energy" or the "Company") (NYSE: BE) on behalf of investors that purchased or otherwise acquired Bloom Energy securities between February 27, 2025 and July 8, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Bloom Energy and have suffered losses, you may CLICK HERE to contact us. You may...
- Lincoln Tech Celebrates 500th Graduate of Johnson Controls AcademyCompanies: Johnson ControlsProgram builds skilled talent pipeline to support increasingly complex, energy intensive environments
- Halliburton LabsHalliburton Labs Announces Three New Portfolio CompaniesCompanies: HalliburtonHOUSTON, August 20, 2026--Halliburton Labs today announced the addition of three companies to its collaborative ecosystem: Electroflow, Osmoses, and SiTration. The selected ventures develop breakthrough technologies that address critical challenges in battery materials, resource recovery, and gas separations. These companies confront the material and process bottlenecks that stand between today’s energy system and tomorrow's opportunities.
- Kaplan Fox & Kilsheimer LLPKaplan Fox Advises First Solar, Inc. (FSLR) Investors of a Securities Class Action Deadline on August 24, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against First Solar, Inc. ("First Solar" or the "Company") (NASDAQ: FSLR) on behalf of investors that purchased or otherwise acquired First Solar securities between February 26, 2025 and February 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in First Solar and have suffered losses, you may CLICK HERE to contact us. You may...
- Hua Medicine Announces 2026 Interim Results- Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue hit RMB378.9 million, up 74% year-on-year. The in-house commercialization drive maintained robust growth with continuously improved operational efficiency. - Expanded manufacturing scale lifted gross profit margin substantially to 61.8%, a year-on-year rise of 7.6 percentage points. - Profit generated from commercial operations doubled year-on-year, and loss narrowed markedly to RMB30.2 million after excluding one-off income, demonstrating a clear path to full-scale profitability. - Selling expense-to-revenue ratio stabilized at 33.5%, reflecting tangible gains from increased marketing efforts and streamlined operations. - Dorzagliatin secured marketing approvals in both the Hong Kong and Macao Special Administrative Regions of China; demonstrating our innovative business model is showing early success and marking a key milestone for global expansion. - A five-year patent term extension was granted for dorzagliatin, extending core patent protection to April 2034. The National Reimbursement Drug List price of the product will remain unchanged for 2026 and 2027, reinforcing long-term commercial profitability certainty. - Topline results from real-world studies further validated the broad applicability, safety and tolerability of dorzagliatin across diverse real-world patient populations. - Multiple combination therapy studies revealed synergistic metabolic benefits when dorzagliatin is paired with oral small-molecule GLP-1 receptor agonists, THR-β agonists and pan-PPAR agonists, tapping into development therapeutic potential in new disease areas including obesity and MASLD. - Clinical development of the second-generation GKA in the United States proceeded smoothly. R&D initiatives for new indications including MODY-2, diabetes prevention, neurodegenerative diseases and frailty were accelerated across the board. SHANGHAI, August 20, 2026 - Hua Medicine (the “Company”, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2026 (the “Reporting Period”), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, HuaTangNing, dorzagliatin tablets), the Company’s core globally first-in-class oral anti-diabetic glucokinase activator (GKA), entered a rapid scale-up phase under proprietary commercialization. Revenue and gross profit both recorded substantial growth with sustained gross margin improvement. The Company achieved critical milestones in global expansion through the commercial launch of dorzagliatin in Hong Kong and Macao SARs. Multiple pivotal clinical datasets were presented at leading international academic conferences, delivering continuous breakthroughs across the full product pipeline. Core operating losses narrowed steadily, while robust cash reserves laid a solid foundation for the Group’s long-term sustainable growth. Dr. Li Chen, Founder and CEO of Hua Medicine, stated: “The first half of 2026 represents a pivotal stage for Hua Medicine as we translate original innovation into marketing value realization. Sales volume and revenue of dorzagliatin grew more than 70% year-on-year, gross margin surpassed 60%, and profit from commercial operations doubled compared with the same period last year. It validates the Company’s successful transition from R&D-innovation-driven growth to rapid commercial development in the chronic disease space. It fully demonstrates that domestically developed first-in-class drugs from China possess strong and sustainable market momentum, backed by national policies that support innovative drugs across the full-value chain. Meanwhile, dorzagliatin was successfully launched in Hong Kong and Macao SARs, officially kicking off our internationalization strategy anchored in Greater China with outreach to Southeast Asian, Spanish-speaking and Portuguese-speaking markets. Chinese original innovative medicines are now deeply participating in the global metabolic disease treatment landscape. Moving forward, rooted in glycemic homeostasis regulation, the Company will advance a new paradigm for diabetes homeostasis-targeted therapy featuring next-generation long-acting GKAs, fixed-dose combinations and combination therapies. We will build a human energy-metabolism health pipeline matrix covering disease prevention, special types of diabetes, fatty liver diseases and steatohepatitis, cognitive impairment and frailty. Leveraging artificial intelligence technologies, the Company will continuously expand the clinical boundaries and application scenarios of its glycemic homeostasis technology platform, and strive to bring China-originated innovative therapies to patients with metabolic diseases at home and abroad.” Business Highlights and Operational Progress 1. Accelerated Proprietary Commercialization with Major Operational Efficiency Improvements - Rapid sales expansion. During the Reporting Period, we sold approximately 3,055,000 packs of HuaTangNing in the first half of 2026, up 73% from 1,764,000 packs sold during the same period in 2025. This rapid sales growth trajectory is further supported by the maintenance of China’s National Reimbursement Drug List (NRDL) price for the 2026 and 2027 calendar years. Regions that already led sales in 2025, coastal areas including Shanghai, Tianjin and Guangdong province and Beijing, continued to deliver strong growth during the reporting period, reflecting the substantial market potential for further market penetration and providing a solid basis for sustained strong growth in the future. - Markedly enhanced profitability driven by scale effects. Relying on expanded production capacity and optimized manufacturing processes, gross margin rose significantly from 54.2% in the first half of 2025 to 61.8%, up 7.6 percentage points; gross profit reached RMB234.3 million, a 99% year-on-year surge. Selling expenses totalled RMB126.9 million, with the ratio of selling expense to revenue standing at 33.5%. Our commercialization efforts achieved profit of approximately RMB107.4 million (as defined by gross profits less selling expenses), doubled from RMB53.7 million in the same period of 2025. as profitability from proprietary commercialization continues to materialize. - Normalized financial performance with healthy cash reserves. Loss before tax stood at approximately RMB30.2 million. Excluding the one-off release of contract liabilities in the corresponding period of 2025 following the termination of the Bayer contract, the loss for the current reporting period is expected to narrow by approximately RMB29.4 million as compared with the adjusted loss of approximately RMB59.6 million for the corresponding period in 2025. Fundamental business operations continued to improve. Cash balances were approximately RMB1,072.9 million as of June 30, 2026 a decrease of RMB19.4 million from bank balances and cash position as of December 31, 2025. Ample liquidity supports domestic market expansion, global clinical R&D, and overseas commercialization in Hong Kong, Macao and Southeast Asia. - Our commercialization team continued to scale. The professional sales team expanded to 187 product representatives, and 75 staff actively engaged in marketing, medical affairs and commercial operation as of June 30, 2026, representing growth of 93% and 79% respectively compared with the same period of 2025. 2. Strengthened Core Intellectual Property Rights and Breakthroughs in Overseas Market Development - Marketing approvals secured and commercialization rolled out in Hong Kong and Macao. Dorzagliatin (brand names: MYHOMSIS(R) was approved for marketing in Hong Kong on February 2026 and in Macao on June 2026. The product has been distributed to hospitals and pharmacies in Hong Kong, with the first prescription issued in August 2026, providing a new treatment option for patients with Type 2 diabetes outside mainland China. - Patent term extension secured to boost long-term commercial certainty. In February 2026, the China National Intellectual Property Administration granted a five year patent term extension for dorzagliatin, extending core patent protection to April 2034. 3. Real-World Clinical Evidence Reinforces the Product’s Differentiated Value The Group continued advancing post-marketing real-world studies of dorzagliatin to further validate its efficacy and safety profiles in complex patient cohorts. - Topline data released from large-scale multi-centre post-marketing real-world study HMM0601. At the 2026 ADA Scientific Sessions, the Company presented results from HMM0601, a large-scale post-marketing real-world study. Across 80 clinical centres in China, HMM0601 enrolled 2024 patients with Type 2 diabetes with mean disease duration of 7.9 years. Over the 52-week treatment period, no drug-related serious adverse events (SAEs) or episodes of severe hypoglycemia were observed; the incidence of clinically meaningful hypoglycemia was below 1%, and no new safety signals were identified compared with the Phase III clinical trials; HbA1c was significantly reduced from baseline, and the proportion of patients achieving HbA1c<7% increased markedly. This provides robust evidence of dorzagliatin’s strong safety and tolerability profile and consistent glycemic control efficacy. - Interim findings disclosed from prospective real-world observational study HMM0701. This study enrolled 255 patients with Type 2 diabetes, the majority of whom had long disease duration and were already receiving multi-drug regimens including insulin. The 6-month interim results of subgroup analysis indicates that dorzagliatin provides meaningful efficacy in glycemic control. Even in patients with severely compromised baseline TIR, clinically meaningful reductions in HbA1c, improved TIR, enhanced β-cell function, and reduced insulin resistance were observed, collectively indicating the restoration of glucose homeostasis. This study provides a solid rationale for a novel glycemic management option in complex T2D cases. - Preparations remain underway for post-marketing study HMM0602. The study is designed to generate further clinical evidence regarding the role of dorzagliatin in restoring glucose homeostasis and its potential contribution to diabetes remission. Research and Development Pipeline and Future Outlook 1. Multiple R&D Innovation Breakthroughs Usher in New Chapters for First-in-Disease Indications - Dorzagliatin for Patients with GCK-MODY Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase release of insulin. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given currently available medications are not effective. In clinical studies with MODY-2 patients, a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate glucagon like peptide 1 (GLP-1) secretion. During the Reporting Period, we continued to advance the regulatory development of dorzagliatin for GCK-MODY in China. Following prior communications with the Center for Drug Evaluation of the National Medical Products Administration, we completed the proposed clinical protocol. We plan to submit an IND application for dorzagliatin in GCK-MODY by December 2026. - Dorzagliatin for Diabetes Prevention Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated the SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients under the leadership of Dr Juliana Chan and Dr Elaine Chow of the Chinese University of Hong Kong. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under intravenous glucose tolerance test and oral glucose tolerance test conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and file IND applications of dorzagliatin for diabetes prevention in China and Asia-Pacific regions thereafter. - Dorzagliatin for Neurodegenerative Diseases MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the United States, and is common in T2D patients with a 45% incidence rate. Development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of MCI and are initiating these first-in-disease clinical studies. Preparation of the clinical study protocol and clinical development plan has been initiated. We expect to launch pre-IND communications with the relevant regulatory authority in the fourth quarter of 2026. - Dorzagliatin for Frailty Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of American older adults and 11% of Asian older adults suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence has suggested a potential relationship between glucokinase activation and a reduced risk of frailty, supporting further investigation of dorzagliatin in this area. We intend to progress the regulatory preparations for an IND submission in 2026. 2. Robust Pipeline Gains Momentum, AI Powers Collaborative Innovation - Fixed Dose Combination of Dorzagliatin and Metformin We are fast forwarding the development of the FDC of dorzagliatin with metformin. An IND with the NMPA has been filed for our FDC with metformin in China in 2025, with an NDA submission planned for 2027. - The 2nd Generation of GKA under Development in the United States HM1005 is our second-generation GKA program based on a sustained-release formulation of dorzagliatin and is being developed as a once-daily oral therapy. In 2025, we successfully initiated MAD clinical study in T2D patients in the United States. As of the date of this report, five cohorts have been completed as planned in the Phase Ib multiple ascending dose study. HM1005 was generally well tolerated across the completed cohorts. We are conducting a subsequent cohort evaluating two 246 mg tablets in the United States. Topline data are expected to be published in the second half of 2026, and we will pursue partnerships to develop the 2nd generation GKA for global markets. - Development of Combination Therapies for Diabetes and Metabolic Diseases We presented three combination therapy studies in animal models of metabolic disorder at 2026 ADA. The combination of dorzagliatin and orforglipron, an oral small-molecule GLP-1 receptor agonist, demonstrated synergistic glycemic control, significantly enhanced β-cell function, and maintained weight loss and lipid-lowering benefits in diet-induced obese (DIO) mice. Notably, the data revealed a compelling dose-sparing effect which directly reduces the overall side-effect burden – particularly common GLP-1-related gastrointestinal adverse events – thereby meaningfully improving long-term patient adherence. These complementary mechanisms across glycemic control, weight loss, and lipid improvement, position the potential combination as a highly effective, well-tolerated, and differentiated oral option for T2D patients with obesity. In the study combining dorzagliatin with the THR-β agonist resmetirom, the combination synergistically improved systemic metabolism and exerted hepatoprotective effects, optimizing glycemic control, regulating lipids, reducing uric acid, and alleviating hepatic fibrosis. This supports the clinical potential of dorzagliatin for T2D patients with MASLD. Additionally, the combination of dorzagliatin with chiglitazar, a pan-PPAR agonist, improves glucose tolerance, reduces insulin resistance, enhances insulin sensitivity and β-cell function, and elevates high-density lipoprotein cholesterol levels in DIO mice model of MASLD. - Integration of AI, LLMs and Clinical Big Data Alongside the continued development of dorzagliatin in research and clinical practice, the Company has continued to invest in the integration of AI, large language models (LLMs) and clinical big data, and has achieved concrete outcomes. We launched our proprietary GK education platform (GK Charger) in 2025. The platform uses natural language interaction to present complex glucokinase relevant knowledge in evidence-based, clinically relevant format that is easy for both physicians and patients to understand. It enables doctors to obtain up to date diagnostic and treatment information, make accurate clinical decisions, and develop individualized treatment plans for patients. Since the launch of GK Charger, the platform has cumulatively responded to more than 3,700 queries. Financial Summary As of June 30, 2026 - Sales volume of HuaTangNing reached approximately 3.055 million packs, up 73% year-on-year, generating revenue of approximately RMB378.9 million, representing a 74% year-on-year increase. - Gross profit totalled approximately RMB234.3 million, up 99% year-on-year, with gross margin rising to 61.8%. - Loss before tax stood at approximately RMB30.2 million, representing a substantial narrowing compared with adjusted loss recorded in the same period of 2025. - Bank balances and cash position were approximately RMB1,072.9 million, maintaining a healthy liquidity profile. - Total expenditures amounted to approximately RMB265.4 million, including selling expenses of approximately RMB126.9 million and research and development expenses of approximately RMB66.8 million. Forward-Looking Statements This document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements. About Hua Medicine Hua Medicine (the “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Drawing on global resources, Hua Medicine partners with high-calibre talent worldwide to develop breakthrough technologies and products that advance innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets) targets the glucose sensor glucokinase, restores glucose sensitivity in patients with type 2 diabetes (T2D), and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin for adult patients with T2D. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral glucose-lowering drug that can be used in patients with T2D with renal function impairment. In February 2026, dorzagliatin (brand name: MYHOMSIS(R), was approved for marketing by the Pharmaceutical Service of the Department of Health of the Government of the Hong Kong Special Administrative Region of the People's Republic of China. In June 2026, dorzagliatin (brand name: MYHOMSIS(R), was approved for marketing by the Pharmaceutical Administration Bureau of the Macao Special Administrative Region of the People's Republic of China. Based on the International Diabetes Federation’s 2025 Diabetes Atlas – 11th Edition, there are approximately 148 million diabetic patients in mainland China, 706,000 diabetic patients in Hong Kong SAR, and 52,000 diabetic patients in Macao SAR as of 2024. For more information Website: www.huamedicine.com Investors Email: [email protected] Media Email: [email protected] Press Disclaimer For accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities. Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional.
- Asia's fashion extravaganza CENTRESTAGE returns in SeptemberAsia’s premier annual fashion event CENTRESTAGE--organised by the Hong Kong Trade Development Council (HKTDC) and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Government of the Hong Kong Special Administrative Region (HKSAR) will return to the Hong Kong Convention and Exhibition Centre (HKCEC) from 2 to 5 September. One of the flagship programmes of the third "Hong Kong Fashion Fest", CENTRESTAGE will bring together some 270 brands from 24 countries and regions and will feature more than 40 spectacular events, including over 30 fashion shows. The number of participating designer brands and fashion shows reached a record high this year, showcasing the vibrancy and international influence of Hong Kong's fashion industry, and strengthening the city’s position as an international trading hub and an East-meets-West centre for international cultural exchange. The fair is open to industry buyers and the public for free, welcoming visitors to experience the unique charm of Asia’s fashion capital in person. Smilely Lam (centre), Associate Executive Director of the HKTDC; Katherine Fang (second left), Chairman of the HKTDC Garment Advisory Committee; Yvonne Ip, Assistant Commissioner for Cultural and Creative Industries (second right); Ryu Seok Chun (far right), Director General of the Korea Trade-Investment Promotion Agency Hong Kong (KOTRA); and Chief Designer XPX Eugene Lam from Hype² pavilion (far left) introduce the highlights of CENTRESTAGE at the press conference. Smilely Lam, Associate Executive Director of the HKTDC, said: “HKTDC is committed to promoting trade development through the extensive global network and years of exhibition experience to actively support Hong Kong fashion brands and designers in expanding into overseas markets. This year marks the 11th edition of CENTRESTAGE. Leveraging on Hong Kong’s role as a superconnector, we would like to utilise CENTRESTAGE to connect the industry with global buyers, partners and media. Through CENTRESTAGE, Hong Kong fashion and design can go further and shine brightly on the world stage.” Inaugural Hype² pavilion harnesses star power and KOL influence With the continuous growth of the global streetwear market and Generation Z consumers increasingly seeking "self-expression" and "emotional value", CENTRESTAGE introduces the Hype² pavilion for the first time this year. This pavilion spotlights fashion labels spearheaded by local celebrities and KOLs, promoting cross-sector collaborations across the fashion & lifestyle, show & entertainment, culture & creative industries. Participating brands include Claro by Rosita Kwok, OGIS by Vincent Wong, PICK AND MATCH by Kelvin Kwan, ROSEMA.ESE X Jaime Cheung by Jaime Cheung and Ariel Leung, and XPX by Pakho Chau and more. Several brands will launch limited-edition or debut products during the fair to further drive excitement. The fair will also host the "Hype² Fashion Show" on 4 September, featuring a joint presentation by more than 10 trend-setting brands. The fair brings together some 270 exhibiting brands from 24 countries and regions. CENTRESTAGE ELITES: KIT WAN STUDIO’s solo fashion show in Hong KongThe grand opening fashion show, CENTRESTAGE ELITES, will take place on the first day of the fair (2 September), putting the spotlight on KIT WAN STUDIOS, a multidisciplinary design and visual art studio led by Kit Wan, a Hong Kong-born creative director and visual artist. The studio's collaborative roster of local superstars is formidable and includes Miriam Yeung, Hins Cheung, MC Cheung, and Panther Chan. The artist’s overseas collaborations also span multiple top-tier events, including designing ‘stage armour’ for artists in Los Angeles at the Grammy Awards and Eurovision in the United Kingdom. Marking his solo fashion show in Hong Kong, the presentation is themed "MUTANT // MYTHOLOGY", connecting the two seemingly unrelated concepts of "mutation" and "mythology". Through three narrative chapters, it presents a cinematic fashion journey, striking a balance between the studio's signature performative showpieces and more-wearable fashion silhouettes. The HKTDC has specially arranged to livestream this grand fashion occasion on the CENTRESTAGE website and Instagram account, the HKTDC’s YouTube channel, Facebook and other official pages, as well as various lifestyle online platforms. During the fair, a dedicated exhibition area will also be set up at the venue to display selected works from CENTRESTAGE ELITES. Kit Wan will attend the fair in person on 4 September to share his experience in expanding into overseas markets and his insights on creative inspiration, to help guide young designers and fashion design students. Korea debuts as "Featured Partner" to present largest-ever pavilion This year’s CENTRESTAGE brings together exhibitors from 24 countries and regions, among which the Faroe Islands, Austria and Slovakia from Europe, the United Arab Emirates from the Middle East, Malaysia from Asia, as well as Colombia from South America will participate for the first time, further broadening the international footprint of CENTRESTAGE. Korea, meanwhile, becomes CENTRESTAGE's “Featured Partner” for the first time, with the Korean Pavilion jointly organised by the Korea Trade-Investment Promotion Agency (KOTRA), HISEOUL SHOWROOM and the Consulate General of the Republic of Korea in Hong Kong, marking the largest pavilion in the event's history. The pavilion brings 12 Seoul-based designer brands, including doucan, ELNORE, Ét demain, HOLYNUMBER7, NUOSMIQ and RE RH'EE. Beyond Seoul, the Gyeonggi Fashion Creative Studio brings 10 local brands, including ARTS DE BASE, PHENOMENON SEEPER and VEGANTIGER, introducing the latest Korean styling aesthetics and high street fashion to Hong Kong. The Korean pavilion will also present a thematic fashion show titled "SEOUListic: The Future is Sustainable" on 4 September (the third day of the fair). In addition to showcasing the creativity and sustainable concepts of Korean designers, Lee Chae-yeon, a former member of the girl group IZ*ONE, will make a special guest performance, fusing fashion and entertainment to highlight the charm of Korean pop culture. The Austrian pavilion, coordinated by Austrian Trade Commission, makes its debut with seven brands, including Woody, which boasts over a century of wooden shoe craftsmanship, and the avant-garde structuralist brand km/a mode. Led by the Australian Fashion Council, the Australian pavilion will present 10 participating brands showcasing a natural and comfortable Australian fashion aesthetic. Meanwhile, the Canadian pavilion, spearheaded by the Consulate General of Canada in Hong Kong and Macao, gathers several high-end, female-founded and female-led brands, including Iris Setlakwe and Devlyn Van Loon. Seven thematic zones feature new "Perfume" zone This year’s CENTRESTAGE features seven thematic zones. The brand-new "Perfume" zone gathers various fragrance brands from around the world, including niche labels from Malaysia, Thailand and Vietnam that are not yet available in Hong Kong, allowing buyers and fashion enthusiasts to extend their fashion experience through scents. The "Craftsmanship" zone is a combination of artisanal techniques and fashion design, featuring first-time Malaysian exhibitor Maswira Majid and local brand Catchu Syvaion, which incorporates craft elements into lingerie design. The "Contemporary" zone brings together brands such as Colombian label STUDIO INGRID BURGOS and Chinese Mainland premium menswear and womenswear brand Langdeng. The "Urban" zone spotlights casual design brands full of metropolitan charm, including local brand COLE COOL. The "Athleisure" zone gathers multiple collections combining sportswear elements and workwear, including local brand Glocal Mahjong. The "Circular Fashion" zone introduces first-time German exhibitor Paulina's Friends and local brand JESSE LEE, showcasing upcycled fabrics combined with 3D printing technology. Furthermore, the "Accessories" zone, which was first introduced last year, has further expanded in scale this year, with American luxury brand Jeremie St. Croix making its debut. Record number of fashion shows gathers industry elites and rising stars This year, CENTRESTAGE will feature more than 40 spectacular events, of which over 30 are fashion shows covering a diverse range of styles, setting a new record for the fair. One of the major highlights, the Fashion Hong Kong Runway Show, will take place on 3 September. Inspired by the theme "Hong Kong Dopamine", it will transform the diversity, aesthetics and energy of this city into a sensory experience. Four local designer brands, including 112 mountainyam, ANGUS TSUI, ARTY:ACTIVE and Z I D I, will present their latest creative collections, interpreting the unique allure of Hong Kong fashion design. In addition, other exciting fashion shows will feature local labels including KEVYIU, VICTOR CHAN STUDIO x atelierYVF, Cixi Jewelry and Cecilia Yau Couture, as well as designs by Paulina's Friends from Germany and Slovak designers Bráz Noémi and Mišena Juhász, showcasing diverse creative design styles from different regions to industry professionals and audiences. CENTRESTAGE will also host a series of talks during the fair, including a "Meet with Designer" session featuring Korean designer Rok Hwang in person on 4 September, who will share his experience in building the ROKH brand and taking it onto the international stage, as well as his observations and insights on the development of the global fashion industry. In addition, organisations including Redress, AiDLab and the Australian Fashion Council will present thematic talks exploring hot topics such as circular fashion and fashion technology. CENTRESTAGE continues to nurture emerging design talent through a series of competitions, including the Hong Kong Young Fashion Designers' Contest (YDC) organised by HKTDC, which is dedicated to providing a platform for young designers to showcase their work. In addition, the "Thread of Creativity – Fashion Design Competition 2026" organised by the Asian New Generation Creativity Design Association will also take place during the fair, allowing young designers to demonstrate their creative talent and inject fresh energy into the industry. In addition, the "Sparkle Charity Foundation x Sparkle Collection: Next In Chinese Style – Young Designer Challenge 2026 Award Presentation Ceremony", initiated by designer brand SPARKLE by KAREN CHAN, will honour the next generation of design talent, promoting the inheritance and innovation of fashion culture while encouraging young designers to fulfil their potential. Other highlights include a fashion showcase organised by the Fashion Farm Foundation, featuring works by designers from the Greater Bay Area, as well as the "Young Knitwear Designers' Runway 2026" organised by the Knitwear Innovation and Design Society (KIDS), showcasing the vitality and development potential of Hong Kong's knitwear fashion industry. The HKTDC Hong Kong Watch & Clock Fair and Salon de TIME (1-5 September), also organised by HKTDC, will be staged concurrently with CENTRESTAGE, allowing visitors to explore the latest watch and clock products alongside fashion brands at the same venue. The CENTRESTAGE Instagram account (@centrestage_hktdc) has been continuously updated with the latest event information and fashion trends. Everyone is welcome to follow the account to stay closely connected with all the latest happenings at CENTRESTAGE. CENTRESTAGE: https://www.hktdc.com/event/centrestage/en CENTRESTAGE Instagram (IG): https://www.instagram.com/centrestage_hktdc/ Fashion Hong Kong: https://www.fashionhongkong.com/ Hong Kong Young Fashion Designers' Contest (YDC): https://www.fashionally.com/en/ Photo download: https://bit.ly/4xUZbMs Smilely Lam (centre), Associate Executive Director of the HKTDC; Katherine Fang (second left), Chairman of the HKTDC Garment Advisory Committee; Yvonne Ip, Assistant Commissioner for Cultural and Creative Industries (second right); Ryu Seok Chun (far right), Director General of the Korea Trade-Investment Promotion Agency Hong Kong (KOTRA); and Chief Designer XPX Eugene Lam from Hype² pavilion (far left) introduce the highlights of CENTRESTAGE at the press conference. The fair brings together some 270 exhibiting brands from 24 countries and regions. The grand-opening fashion show, CENTRESTAGE ELITES, will be held on 2 September, spotlighting KIT WAN STUDIOS — a multidisciplinary design and visual-arts studio led by Kit Wan. The STUDIO’s new collection, "MUTANT // MYTHOLOGY," was previewed at today’s press conference. Kim Youngseok (centre) and Wilfred Chung (right), Deputy Director and Project Manager of the Korea Trade-Investment Promotion Agency (KOTRA), together with guest host Annie Lee (left), introduce the highlights of the Korean Pavilion. Girl group VIVA wearing outfits from participating Korean brands at the press conference, showcasing the allure of Korean fashion. Artist Jeffrey Ngai introduces CENTRESTAGE's newly launched Hype² pavilion. Media enquiries PURPLE: Fiona Wong Tel: (852) 9221 1056 Email: [email protected] Yannis Sin Tel: (852) 6226 3398 Email: [email protected] HKTDC’s Communications & Public Affairs Department: Katy Wong Tel: (852) 2584 4524 Email: [email protected] Jane Cheung Tel: (852) 2584 4137 Email: [email protected] HKTDC Newsroom: https://mediaroom.hktdc.com/en About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn About Cultural and Creative Industries Development Agency (CCIDA) The Cultural and Creative Industries Development Agency (CCIDA), formerly known as Create Hong Kong (CreateHK) since 2009, was established in June 2024. CCIDA is a dedicated office under the Culture, Sports and Tourism Bureau of the Government of the Hong Kong Special Administrative Region (HKSAR Government) to provide one-stop services and support to the cultural and creative sectors with a mission to foster a conducive environment in Hong Kong to facilitate development of the arts, culture and creative sectors as industries. CCIDA’s strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and multi-disciplinary collaboration, promoting industrialisation of the arts, culture and creative sectors under the industry-oriented principle, and fostering a creative atmosphere in the community, thereby reinforcing Hong Kong as Asia’s creative capital and our positioning as the East-meets-West centre for international cultural exchange. About Hong Kong Fashion Fest Announced by the Hong Kong Special Administrative Region Chief Executive in the 2023 Policy Address, "Hong Kong Fashion Fest" will be organised to develop Hong Kong into a fashion design hub in Asia. Through consolidating various fashion design events and introducing innovative elements and affiliate activities annually, the Hong Kong Fashion Fest promotes Hong Kong’s fashion and textile design brands and boosts Hong Kong’s position as a prime destination for hosting mega cultural and creative events. Under the theme "Rhythm of the Heart", the third edition of Hong Kong Fashion Fest will be held from 1 to 14 September 2026 at various landmarks in Hong Kong. The event will bring together eight flagship programmes organised by six industry organisations and, for the first time, will be combined with CENTRESTAGE - the annual fashion extravaganza organised by the Hong Kong Trade Development Council - to generate stronger synergies. The event will attract fashion design industry players from all over the world to come to Hong Kong; foster collaboration, innovation and business opportunities; establish platform for local and international fashion designers and brands and connect with different sectors in the fashion design industry of Hong Kong, the Chinese Mainland and overseas, thereby consolidating Hong Kong’s position as the East-meets-West centre for international cultural exchange. Disclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee.
- Offshore Wind Market to Reach $208.33 Billion, at a 15.4% CAGR by 2035 | MarketsandMarkets™According to MarketsandMarkets, the global Offshore Wind Market size is projected to reach USD 208.33 billion by 2035 from USD 57.51 billion in 2026, at a CAGR of 15.4% during the forecast period. The rapid expansion of renewable energy generation, growing energy security concerns, ambitious decarbonization targets, and increasing investments in offshore renewable infrastructure are significantly driving demand for offshore wind projects across global markets. As countries accelerate the transition toward low-carbon energy systems, offshore wind is becoming a critical source of large-scale renewable electricity generation due to its high capacity factors, abundant wind resources, and ability to support long-term energy sustainability goals.
- Important Notice to Long-Term Shareholders of Bloom Energy Corporation (NYSE: BE); Primoris Services Corporation (NYSE: PRIM); Roblox Corporation (NYSE: RBLX); and Symbotic Inc. (NASDAQ: SYM): Grabar Law Office is Investigating Claims on Your BehalfSHAREHOLDER NOTICE: Bloom Energy Corp. (NYSE: BE); Primoris Services Corp. (NYSE: PRIM); Roblox Corp. (NYSE: RBLX); and Symbotic Inc. (NASDAQ: SYM)